Current Report · Items 5.07, 9.01 · 8-K
Palatin Technologies, Inc.
Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On July 28, 2026, Palatin Technologies, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the following:…
Filed Aug 3, 2026Accepted Aug 3, 2026, 6:04 AM EDTCIK 911216Accession 0001493152-26-035722
Company context
We are a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
Current securities
Historical securities (5)
Registered securities in this filing
PALATIN TECHNOLOGIES, INC. · 8-K · Filed 2026-08-03
As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.
Common Stock, par value $0.01 per share
- Symbol
- PTN
- Exchange
- NASDAQ
- Classification
- COMMON
Filing context
Context: AsOf2026-07-28
Dimensions: Not supplied
Accession 000149315226035722 · 1 registered-security cover member
Read the exact SEC filing ↗Disclosure sections
Items 5.07, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.07Item 5.07 - Submission of Matters to Vote
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
July 28, 2026, Palatin Technologies, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”)
to consider and vote on the following: (1) election of directors (“Item 1”), (2) ratification of the appointment of the Company’s
independent registered public accounting firm for the fiscal year ending June 30, 2026 (“Item 2”), (3) approval of an amendment
to the Company’s 2011 Stock Incentive Plan, as amended and restated, to increase the number of shares available for equity awards
by 260,000 shares (“Item 3”), and (4) advisory approval of the compensation of the Company’s named executive officers
for the fiscal year ended June 30, 2025 (“Item 4”).
As
of June 22, 2026 (the “Record Date”), the total number of votes entitled to be cast at the Annual Meeting was 1,842,625,
consisting of (i) 1,779,275 shares of Common Stock or equivalents thereof, each share entitled to one vote, (ii) 4,030 shares of Series
A Preferred Stock, each share entitled to approximately 0.38 votes, representing an aggregate of 1,534 votes, and (iii) 3,400 shares
of Series D Preferred Stock, each share entitled to approximately 18.18 votes per share, representing an aggregate of 61,816 votes. At
the Annual Meeting, the total number of votes present in person or by proxy was 1,000,506, comprising 54.3% of the votes entitled to
be cast at the Annual Meeting.